Healthcare / Diagnostics & ResearchCanadian Sec
$0.58
-0.01 (-1.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-986915.00 · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$61M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-110.7%
↓Gross Margin
N/A
•Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+52.0%
FCF CAGR
—
FCF margin
-711.1%
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $154216.0 · net income $-1.9M · FCF $-1.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $154216.00 | $154216.00 | $163220.00 | $153492.00 | $43933.00 |
| Net Income | $-1.9M | $-1.9M | $-1.4M | $-1.8M | $-1.5M |
| EBITDA | $-1.5M | $-1.5M | $-919047.00 | $-1.3M | $-1.2M |
| EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Operating Margin | -1237.3% | -1237.3% | -806.7% | -1128.4% | -3193.7% |
| Net Margin | -1249.7% | -1249.7% | -874.5% | -1200.2% | -3309.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | -1.32 | -0.72 | -1.65 |
| Current Ratio | 1.20 | 1.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.1M | $-1.1M | $-986915.00 | $-919720.00 | $-1.3M |
| Returns | |||||
| ROE | -110.7% | -110.7% | 234.1% | 160.3% | 228.7% |
| Valuation | |||||
| P/B | 30.29 | 30.29 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -5.5% | -5.5% | 6.3% | 249.4% | — |
| EPS Growth | 0.0% | 0.0% | 0.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+93.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.02
Residual
+93.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.